Avedro Acquires Assets of IROC Innocross AG, Including its UV-X Line of Cross-Linking Devices

Avedro Acquires Assets of IROC Innocross AG, Including its UV-X Line of Cross-Linking Devices

September 3, 2014

Avedro and IROC Innocross Are the World's Leading Corneal Cross-Linking Device Companies

Waltham, Massachusetts, USA, Sep 03, 2014 Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that it has purchased the assets of IROC Innocross AG, of Zug, Switzerland.

Oasys Water Continues Growth and Commercialization Momentum in Global Markets

Oasys Water Continues Growth and Commercialization Momentum in Global Markets

September 2, 2014

BOSTON--(BUSINESS WIRE)--Oasys Water, a world leader in innovative solutions for water treatment and desalination, today announced its first international commercial application underscoring successful partnership development efforts in the Chinese market. The Changxing Power Plant, located in China’s northern Zhejiang province, will use Oasys Water’s patented technology to treat the coal-fired power plant’s wastewater from flue gas desulfurization (FGD).

Joule to Host Strategic Seminar on Climate Change in Norway, Featuring Jeffrey Sachs

Joule to Host Strategic Seminar on Climate Change in Norway, Featuring Jeffrey Sachs

August 28, 2014

Bedford, MA - Joule, the innovator of a CO2 -to-fuels reverse combustion process, will convene industry and political leaders for a seminar in Oslo, Norway: “Converting Words to Action on Climate Change: The Role of Technology.” The event will be headlined by Professor Jeffrey Sachs, senior United Nations advisor and director of the Sustainable Development Solutions Network (SDSN).

Seres Health to Present Clinical Findings at ICAAC 2014 Conference

Seres Health to Present Clinical Findings at ICAAC 2014 Conference

August 28, 2014

CAMBRIDGE, Mass., Aug. 28, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, announced today that Dr.

Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration

Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration

August 26, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDQ: CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc. for the clinical progression of AVP-786. The milestone is a result of Avanir initiating dosing in a Phase 2 clinical trial with AVP-786 for the adjunctive treatment of major depressive disorder.

Flagship Ventures Appoints Agricultural Industry Leader Robert Berendes as Venture Partner

Flagship Ventures Appoints Agricultural Industry Leader Robert Berendes as Venture Partner

August 25, 2014

CAMBRIDGE, Mass., Aug. 25, 2014 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, today announced the appointment of Dr. Robert Berendes as a Venture Partner. Dr. Berendes, who most recently was a member of the executive team at Syngenta, will provide strategic counsel and support to the Flagship team. Through board and advisory roles, he will engage with portfolio companies focused on innovations that address sustainability in the energy, water, and agriculture/nutrition sectors.

Joule Achieves Industry First With A 100% Increase In Photosynthetic Efficiency

Joule Achieves Industry First With A 100% Increase In Photosynthetic Efficiency

August 15, 2014

Bedford, MA – August 15, 2014 – Overcoming the limitations of photosynthesis, Joule has successfully co-opted nature’s primary energy capture process at unprecedented efficiencies for direct, continuous fuel production. This includes the engineering of a photosynthetic biocatalyst able to divert 95% of fixed carbon normally converted to biomass directly to fuel, and the industry first improvement of its photon energy conversion efficiency.

Allergan Acquires LiRIS® Program from TARIS Biomedical®

Allergan Acquires LiRIS® Program from TARIS Biomedical®

August 13, 2014
  • TARIS LiRIS® Program in Phase 2 Clinical Development for the Localized Treatment of Interstitial Cystitis / Bladder Pain Syndrome
  • Acquisition Enhances Allergan’s Leadership Position in Urology and Reinforces the Company’s Commitment to Developing Innovative Treatments to Address Important Medical Needs

Seventh Sense Biosystems Closes $16 Million Series B Financing

Seventh Sense Biosystems Closes $16 Million Series B Financing

August 13, 2014

CAMBRIDGE, Mass., Aug 13, 2014 (BUSINESS WIRE) -- Seventh Sense Biosystems, Inc. (7SBio), the pioneering developer of virtually painless blood collection and diagnostic platforms, today announced a $16 million Series B financing from a syndicate of global leaders in diagnostic technologies, pharmaceuticals and clinical diagnostic laboratory services.

Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation

Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation

August 13, 2014

CAMBRIDGE, Mass., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AG-221 for the treatment of patients with acute myelogenous leukemia (AML) that harbor an isocitrate dehydrogenase-2 (IDH2) mutation. AG-221 is a first-in-class, oral, selective, potent IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies.